2020
Clinical implication of serum CA125 for the prediction of malignancy in mucinous cystic neoplasms of the pancreas
Deng S, Fan Z, Gong Y, Cheng H, Jin K, Qian Y, Xiao Z, Liu Y, Wang R, Zheng Y, Ni Q, Yu X, Liu C, Luo G. Clinical implication of serum CA125 for the prediction of malignancy in mucinous cystic neoplasms of the pancreas. Experimental And Therapeutic Medicine 2020, 20: 158. PMID: 33093896, PMCID: PMC7571373, DOI: 10.3892/etm.2020.9287.Peer-Reviewed Original ResearchMucinous cystic neoplasmsSerum CA125Carcinoembryonic antigenMalignant changeReceiver operating characteristicCystic neoplasmsCarbohydrate antigenPredictive value of CA125Serum carbohydrate antigenSerum carcinoembryonic antigenPredictive of malignancyValue of CA125CA19-9Predicting malignancyMalignant potentialInvasive groupSerum levelsCA125Grade groupPredictive valueSerumPredictive roleHigh gradeClinical implicationsAntigen
2017
Distribution of Lewis and Secretor polymorphisms and corresponding CA19‐9 antigen expression in a Chinese population
Guo M, Luo G, Lu R, Shi W, Cheng H, Lu Y, Jin K, Yang C, Wang Z, Long J, Xu J, Ni Q, Liu C, Yu X. Distribution of Lewis and Secretor polymorphisms and corresponding CA19‐9 antigen expression in a Chinese population. FEBS Open Bio 2017, 7: 1660-1671. PMID: 29123975, PMCID: PMC5666394, DOI: 10.1002/2211-5463.12278.Peer-Reviewed Original ResearchCarbohydrate antigen 19-9 as a prognostic biomarker in pancreatic neuroendocrine tumors
Luo G, Jin K, Cheng H, Liu C, Guo M, Lu Y, Yang C, Xu J, Wang W, Gao H, Zhang S, Long J, Xu J, Ni Q, Chen J, Yu X. Carbohydrate antigen 19-9 as a prognostic biomarker in pancreatic neuroendocrine tumors. Oncology Letters 2017, 14: 6795-6800. PMID: 29163700, PMCID: PMC5688789, DOI: 10.3892/ol.2017.7071.Peer-Reviewed Original ResearchPancreatic neuroendocrine tumorsCA19-9 levelsCA19-9Carbohydrate antigen 19Overall survivalPrognostic factorsAntigen 19Neuroendocrine tumorsPrognostic biomarkerMajority of PNETsTumor node metastasis (TNM) stage IIIROC curveBaseline CA19-9 levelsSerum CA19-9 levelsMetastasis stage IIIPrimary end pointAdverse prognostic factorPatients' overall survivalExpression levelsConsecutive patientsPresent studySingle institutionAbnormal elevationStage IIINormal range
2016
Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping
Luo G, Guo M, Jin K, Liu Z, Liu C, Cheng H, Lu Y, Long J, Liu L, Xu J, Ni Q, Yu X. Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping. Pancreatology 2016, 16: 1057-1062. PMID: 27692554, DOI: 10.1016/j.pan.2016.09.013.Peer-Reviewed Original ResearchConceptsDetect pancreatic cancerCut-off valueSensitivity of CA19-9CA19-9Pancreatic cancerEffectiveness of CA19-9Secretor genotypeStaging of pancreatic cancerII pancreatic cancerDetection of stage INegative predictive valueCohort of subjectsCA19Carbohydrate antigenStage IPredictive valueSanger sequencingCancerSecretor statusSecretorEarly detectorGenotypic backgroundGroup
2015
Metabolic tumor burden is associated with major oncogenomic alterations and serum tumor markers in patients with resected pancreatic cancer
Shi S, Ji S, Qin Y, Xu J, Zhang B, Xu W, Liu J, Long J, Liu C, Liu L, Ni Q, Yu X. Metabolic tumor burden is associated with major oncogenomic alterations and serum tumor markers in patients with resected pancreatic cancer. Cancer Letters 2015, 360: 227-233. PMID: 25687883, DOI: 10.1016/j.canlet.2015.02.014.Peer-Reviewed Original ResearchConceptsMetabolic tumor burdenMetabolic tumor volumeSerum tumor markersTumor burdenTumor markersPancreatic cancerAbnormal expressions of TP53Abnormal expressionMonitoring treatment responsePancreatic cancer patientsProgression of pancreatic cancerExpression of TP53Tumor volumeCA19-9SMAD4/DPC4 geneTreatment responseCancer patientsDisease progressionPET/CTPredictive significanceSurvival rateLethal diseasePatientsCancerSerum
2014
Metabolic tumour burden assessed by 18F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection
Xu H, Chen T, Wang W, Wu C, Liu C, Long J, Xu J, Zhang Y, Chen R, Liu L, Yu X. Metabolic tumour burden assessed by 18F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection. European Journal Of Nuclear Medicine And Molecular Imaging 2014, 41: 1093-1102. PMID: 24522797, DOI: 10.1007/s00259-014-2688-8.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntigens, Tumor-Associated, CarbohydrateCarcinoma, Pancreatic DuctalFemaleFluorodeoxyglucose F18HumansMaleMiddle AgedMultimodal ImagingPancreatic NeoplasmsPositron-Emission TomographyPostoperative PeriodRadiopharmaceuticalsTomography, X-Ray ComputedTreatment OutcomeTumor BurdenConceptsSerum CA19-9 levelsRecurrence-free survivalMetabolic tumor volumeCA19-9 levelsMetabolic tumor burdenPancreatic ductal adenocarcinomaResectable pancreatic ductal adenocarcinomaTumor burdenOverall survivalTumor sizePancreatic ductal adenocarcinoma patientsSerum CA19-9Predicting overall survivalPancreatic cancer outcomesOperating characteristic analysisPredictive of outcomePET/CT examinationRadical pancreatectomyTumor volumeCA19-9Predicting OSSurrogate markerDuctal adenocarcinomaTLGMultivariate analysis